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Mechanisms underlying delays in resolution programs of inflammation are of interest for many diseases.
Here, we addressed delayed resolution of inflammation and identified specific microRNA
(miR)-metabolipidomic signatures. Delayed resolution initiated by high-dose challenges decreased
miR-219-5p expression along with increased leukotriene B4 (5-fold) and decreased (,3-fold) specialized
pro-resolving mediators, e.g. protectin D1. Resolvin (Rv)E1 and RvD1 (1 nM) reduced miR-219-5p in
human macrophages, not shared by RvD2 or PD1. Since mature miR-219-5p is produced from pre-miRs
miR-219-1 and miR-219-2, we co-expressed in human macrophages a 5-lipoxygenase (LOX)
39UTR-luciferase reporter vector together with either miR-219-1 or miR-219-2. Only miR-219-2 reduced
luciferase activity. Apoptotic neutrophils administered into inflamed exudates in vivo increased
miR-219-2-3p expression and PD1/NPD1 levels as well as decreased leukotriene B4. These results
demonstrate that delayed resolution undermines endogenous resolution programs, altering miR-219-2
expression, increasing pro-inflammatory mediators and compromising SPM production that contribute to
failed catabasis and homeostasis.
T
heacuteinflammatoryresponseisprotectiveandevolvedtorepairinjuryandeliminateinvadingorganisms
(for further details, see ref.1). Ideally it is self-limited and leads to complete resolution of inflammatory
infiltrates and clearance of cellular debris so tissues can return to homeostasis, aprocess historically defined
as resolution
1,2. Yet, when the magnitude and duration of the inflammatory insult is in excess, chronic inflam-
mationandtissuedamagecanensuethatfurtheramplifiesinflammation
1,3–6.Theresolutionphasewaspreviously
thought to be passive
1,7. Evidence now indicates that resolution of inflammation is an active biosynthetic,
programmed response, regulated by production and novel actions of the specialized pro-resolving mediators
(SPM) as well as specific peptide mediators identified to date (recently reviewed in
7,8). During self-limited
inflammation,SPMarebiosynthesizedinresolvingexudatesfromessentialfattyacids.Theseincludethelipoxins
(LX)fromarachidonicacid,aswellasresolvins(Rv),protectins(PD)andmaresins.Thesenovelfamiliesofpotent
mediators from omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) were originally iden-
tifiedininflammatoryexudates
7.EachfamilyintheSPMgenuspossessesdistinctchemicalstructures,andpotent
bioactive members stereoselectively activate specific G-protein coupled receptors (GPCR). SPM are protective
in vivo and act locally to control exudate leukocyte trafficking, pain and enhance efferocytosis (reviewed in
7).
Recently, intracellular signaling mechanisms of SPM were found to involve microRNAs (miRs)
9,10. For example,
RvD1 regulates miR-208 in human macrophages in a GPCR-dependent manner, controlling release of the anti-
inflammatory cytokine IL-10
10.
We introduced and defined, earlier, quantitative resolution indices that take into account temporal cellular
trafficking and chemical mediators (i.e. SPM and cytokines/chemokines) within exudates
11. These indices define
specific actions of endogenous pro-resolving mediators as well as local actions of pharmacologic agents within
resolution
11,12 and are defined as ymax, maximal neutrophil numbers that are present in the exudates; Tmax, time
when ymax occurs; and the resolution interval (Ri) from Tmax to T50 when neutrophil numbers reach half ymax.
Only a few of today’s widely used pharmacopoeia have been assessed for their impact in programmed resolu-
tion
11,12. Some delay resolution, e.g. NSAIDs, while others, e.g. resolvins, protectins and aspirin, stimulate
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SCIENTIFIC REPORTS | 2 : 639 | DOI: 10.1038/srep00639 1resolution, shortening the resolution interval (Ri). Hence, theseindi-
ces were employed recently to establish a new system to assess the
actions of a wide range of drugs and endogenous mediators in reso-
lutionusingdifferentialchallengesofthehostwithhighvs.lowdoses
(e.g. 10 vs. 1 mg) of zymosan
13,14.
Mechanisms that underlie self-limited resolution versus its
unwanted delay or failure are of considerable interest, because it is
now well appreciated that persistent inflammation plays a central
role in many diverse diseases including neuroinflammation, cardio-
vascular, metabolic syndrome as well as the classic inflammation-
associated diseases
4,7. Along these lines, miRs are involved in regu-
latingtheoverallimmunesystem
15–17andarethuscompellingtargets
for investigating initiation of acute inflammation as well as resolu-
tion circuits
9,10. Recently, we identified the first miR signature linked
to resolution employing self-limited acute inflammation. These
include miR-219-5p, miR-208, miR-146b, and miR-21, which each
regulate effector molecules and were validated in both mouse exu-
dates in vivoand human macrophages incontrolling localmediators
and signaling. MiRs are known to regulate several gene targets and
are thus associated with networks of gene products. For example,
miR-146b, miR-208, and miR-219 are associated with genes invol-
ving NF-kB, IL-10 and 5-LOX, respectively
9. We identified a novel
resolution circuit where the SPM resolvin D1 (7S,8 R,1 7 S-trihy-
droxy-4Z,9 E,1 1 E,1 3 Z,1 5 E,1 9 Z-docosahexaenoic acid) activates
its receptors on human macrophages to regulate miR-219-5p
9. Two
hairpin miR-219 precursor structures are found on different chro-
mosomes, miR-219-1 on chromosome 6 (MI0000296) and mir-219-
2 on chromosome 9 (MI0000740). miR-219-1 and miR-219-2 share
the mature 5p miR whereas they each generate distinct mature 3p
miRs
18. In the present report, we addressed whether these miRs
regulated in self-limited inflammation are also involved in delayed
resolution and determined differential miR expression and lipid
mediator (LM)-metabolipidomics during both self-limited and
delayed resolution. We also present evidence that apoptotic PMN
activate resolution programs via miR-219-2 and regulate LM pro-
duction in both the initiation and resolution of acute inflammatory
responses.
Results
Delayed resolution dysregulates microRNA and lipid mediator
profiles. Since select miR (miR-21, miR-146b, miR-208 and miR-
219-5p validated in mouse exudates and human macrophages)
profiles are temporally regulated in acute self-limited inflam-
mation
9, we investigated them during delayed resolution. To this
end, we used differential magnitudes of host challenge and
obtained exudates from each, namely self-limited (1 mg zymosan)
and delayed resolution (10 mg zymosan) with mice challenged at a
time course of 4, 12, 24, and 48 hrs for direct comparison. In self-
limited acute inflammation, there was a rapid and robust increase in
neutrophil (PMN) numbers that peaked at 12 hrs followed by a
steady decline, giving a resolution interval (Ri) 5 12 hrs (Figure 1
a), results consistent with those established for acute inflammatory
murine peritonitis
11. The high-dose challenge group that gave de-
layed exudate resolution
13,19,20 exhibited a less robust initial increase
inPMNthatremainedelevatedfortheentiretimecourse(4–48 hrs).
Representative flow cytometry dot plots of exudate cells obtained at
48 hrs indicated that the delayed resolution challenge contained
predominantly PMN, unlike the self-limited exudates that had
fewer PMN (18.0 6 3.5 3 10
6 vs. 2.0 6 0.4 3 10
6 cells/murine
exudate) and increased numbers of macrophages (Figure 1 b). We
next investigated macrophage subsets in the groups of self-limited
anddelayedresolution.Resolvingmacrophages,characterizedbyF4/
80 positive and CD11b
low staining
21–23, were found significantly
increased between 12 and 24 hrs from 1.9% to 6.1% of the F4/80
cells in the self-limited exudates. In contrast, F4/80
1CD11b
low
macrophages in the group with delayed resolution significantly
decreased at these time intervals from 3.2% to 1.6% (Figure 1 c).
M1 markers including COX-2 and MHC II
24,25 were increased in
the delayed resolution group at 24 hrs post zymosan challenge
(Figure 1 d,e). Together these results indicate that the high dose
challenge led to a reduction in number of resolving macrophages
and an increase in M1 macrophages in the inflammatory exudates
that suggests a contribution to the delayed resolution status. More-
over, these results showed that higher dose zymosan was associated
with sustained PMN accumulation and reduced resolving macro-
phages that might contribute to the delayed or failed resolution
status.
Next, the exudates from delayed resolution challenge had signifi-
cantly lower expression of miR-219-5p, miR-208, but not miR-21 at
the assessed time intervals (4,12,24, and 48 hrs) compared to the
exudates of the self-limited group (Figure 1f). As early as 4 h after
high-dose challenge, miR-219-5p expression in the exudates was ,2
logorderslowerthanintheself-limitedresolvingexudates(Figure1f,
upper left panel inset). Using lipid mediator metabolipidomics, we
identified a number of cyclooxygenase (COX)- and lipoxygenase
(LOX)-derived mediators including PGE2, LTB4 and PD1/NPD1
present within 3 mL aliquots of these lavage exudates (Figure 2
and Supplementary Table 1). These were identified using published
physical criteria established for LM
26 as shown for LTB4 and PD1/
NPD1(Figure2aandb)thatincludedatleastsixdiagnosticionsand
matching chromatographic retention of authentic LM and synthetic
reference materials. Using multiple reaction monitoring (MRM),
we quantified the LM identified in exudates from both self-resolving
and delayed resolution. We found that PGE2 (2,0736316 vs. 6,7396
1,089 pg/exudate) and 15-HETE (1,0976101 vs. 3,1296232 pg/
exudate) were significantly increased in delayed (i.e. high-dose chal-
lenge) compared to the self-limited response (Figure 2 d). In addi-
tion, targeted 5-LOX-derived products from each of the endoge-
nous LM-metabolomes, namely AA, EPA and DHA metabolomes
26,
including LTB4 (7416168 vs. 12,07061,904 pg/exudate), 5-HETE
(2,7116365 vs. 14,06861,773 pg/exudate) from AA, 5-HEPE (6,0366
620 vs. 22,79963,531 pg/exudate) from EPA, 7-HDHA (245646 vs.
2,6146147 pg/exudate) and 4-HDHA (16,49165,222 vs. 40,8186
2,649 pg/exudate) from the DHA metabolome were all significantly
increased in the delayed versus self-limited groups (Figure 2 e). Of
interest, LXA4 levels were significantly higher in delayed (70625
vs. 289667 pg/exudate) compared to self-limited responses. In
comparison, DHA-derived SPM including PD1/NPD1 (1,1406
330 vs. 3246108 pg/exudate), RvD1 (23610 vs. 861p g / e x u d a t e )
and RvD5 (177693 vs. 86625 pg/exudate) were all reduced in the
high-dose challenge (Figure 2 f). Additionally, we determined the
ratios of pro-resolving/pro-inflammatory mediators and found
that these ratios were significantly lower in the peritoneal lavage
obtained from mice challenged with high-dose zymosan (Figure 2
c). LMs were also quantified at 12 hrs (Fig 2 g–i) and 24 hrs (Fig 2
j–l) post zymosan initiation. In delayed resolution, PGE2,L T B 4,5 -
HETE and 7-HDHA were significantly higher at 12 hrs (Figure 2
g,h). Other targeted 5-LOX derived products (e.g. 7-HDHA and 4-
HDHA) gave an increased trend in delayed resolution compared
to self-limited challenges. PGE2, 5-HETE and 5-HEPE were sig-
nificantly increased at 24 hrs in the high dose challenge (Figure 2
j,k). PD1 and RvD6 were identified but were not significantly
different between the two challenges at 12 and 24 hrs (Figure 2
i,l). Notably, there was an inverse correlation between 5-LOX
derived products and miR-219 expression throughout the time
course. Together, these results indicate that delayed resolution
from high-dose challenge was associated with both dysregulated
miR and lipid mediator profiles.
Given that RvD1 regulates expression of select miRs including
miR-146b, miR-21, miR-208 and miR-219-5p
9, we investigated
whether this action was shared with other SPM and translates
to human macrophages. RvE1 also decreased miR-219-5p and
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 639 | DOI: 10.1038/srep00639 2Figure 1 | Specific miRs are temporally and differentially regulated in peritoneal inflammatory exudates. Peritonitis was initiated via intra-peritoneal
injection of zymosan (1 mg/mouse, black or 10 mg/mouse, gray). Exudates were collected at 4, 12, 24, and 48 hrs. (a) PMN were enumerated.
(b) Representative flow cytometry dot plot of exudate cells at 48 hrs. (c,d,e) macrophages subsets were characterized using F4/80
1 CD11b
low (c) F4/
80
1COX-2
1(d)andF4/80
1MHCII
1(e).Blackbars,self-limited;graybars,delayedresolution.Resultsaremean6SEMofn54,separatemice.**P,0.01
12 vs. 24 hr self-limited. 1 P,0.05 12 vs. 24 hr delayed resolution. { P,0.05 24 hr self-limited vs. 24 hr delayed resolution. (f) miRs were isolated from
exudate cells at 4, 12, 24 and 48 hrs and analyzed by qPCR. Results are mean 6 SEM, n54 separate mice. *P,0.05, **P,0.01, ***P,0.001, self-limited
versus delayed resolution zymosan challenge. S.L., self-limited; D.R., delayed resolution.
www.nature.com/scientificreports
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146b and miR-21 expression with no apparent regulation of miR-
219-5p (Figure 3a). These results indicate that each SPM regulates a
distinct panel of miRs highlighting separate mechanisms for each
SPM that are produced from different precursors, EPA or DHA.
miR-219-2 directly targets the 39UTR of 5-LOX. miR-219-5p was
decreased in delayed resolution that correlated with an increase in
LTB4 ,a bioactive product of 5-LOX (Figure 1 and 2). SincemiR-219
produces miR-219-5p and miR-219-3p, while miR-219-2 generates
miR-219-5p and miR-219-2-3p (Supplementary Figure S2a online),
Figure 2 | Differential profiles of SPM and their biosynthetic pathway markers in inflammatory exudates. Lavage exudates (3 mL) collected in 5 mL
lavages from the peritoneum at 4 hrs were subjected to LC-MS-MS lipidomics. Bioactive lipid mediators and precursor/pathway marker were identified
using previously established criteria
26. (a,b) Representative tandem mass spectra of LTB4 and PD1 employed for identification. (c–l) Quantification was
achieved by multiple reaction monitoring of Q1: M–H (parent ion), Q3: diagnostic ion in the MS-MS (daughter ion). (d–f)4 hr, (g-i)12 hr , (j–l)24 hr
exudates.(c)Ratiosofpro-resolvingversuspro-inflammatorymediators.Resultsaremean6SEM,n54separatemurineexudates.*P,0.05,**P,0.01,
***P,0.001, self-limited versus delayed resolution challenge. Black bars, self-limited; Gray bars, delayed resolution.
www.nature.com/scientificreports
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MicroTar) to predict which miR directly targets 5-LOX. In silico
analysis suggests that miR-219-2-3p targets 5-LOX with a binding
context score ,71 (Supplementary Figure S2 online) whereas other
select miRs (miR-21, miR-208, miR-146b, miR-219-3p, and miR-
219-5p) did not have the predicted binding sites on the 39UTR of
human5-LOX.Co-expressionofmiR-219-2inhumanmacrophages
transfected with 5-LOX 39UTR-luciferase vector resulted in a
significant reduction in luminescence (,40%, p,0.05) compared
to control vector-transfected macrophages (Figure 3 b). In con-
trast, miR-219-1, miR-146b, miR-208 or mock did not reduce
luminescence, which confirmed the results of the target prediction.
We also questioned whether miR-219-2 regulates COX metabolic
pathway. In silico analysis predicted that there is a poorly con-
served binding site on COX-2 39UTR for miR-219-2, with a low
context score ,15. Luciferase assay showed that miR-219-2 did
not change the 39UTR reporter activities of either COX-1 or COX-
2 (Figure 3 c). Together, these results indicate that the 39UTR of 5-
LOX but not COX-2 is a direct target for miR-219-2.
miR-219-2 modulates expression of enzymes required for LM
biosynthesis. We next questioned whether miR-219-2 also
regulated additional enzymes associated with LM biosynthesis and/
or further metabolism (i.e. metabolic inactivation). To address this,
humanmacrophagesweretransfected witheithermockormiR-219-
2 vectors for 72 hrs. miRs and mRNAs were then harvested from
macrophagesandanalyzedviaqPCR.miR-219-2overexpressionwas
validated by significant increases of miR-219-5p (,1.8 for an 80%
increase above mock) and miR-219-2-3p (,2.5 or 150% increase
above mock) expression (Figure 4 a). Additionally, miR-219-2
significantly decreased 5-LOX mRNA and protein (Figure 4 b).
Overexpression of miR-219-2 decreased COX-2 mRNA expression
by ,20%, without significant changes in protein levels (Figure 4 c,d).
Overexpression of miR-219-2 led to increased mRNA 15-LOX-I
(,50%), 15-LOX-II (,30%), and 12-LOX (,30%) expression com-
pared to mock transfections (Figure4 ca n dS 3 ) .D e c r e a s e de x p r e s s i o n
was obtained for LTA4 hydrolase (-LTA4H) by ,20%, and also the 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) ,40% compared to
mock transfection (Figure 4c). Importantly, overexpression of miR-219-
2 did not significantly modulate the protein levels of 12-LOX, 15-LOX,
LTA4H and 15-PGDH 72 hrs post transfection (Figure 4 d) and
suggests that regulation of these proteins may have different time
courses than 5-LOX. Together, these results indicate that miR-219-2
selectively regulates 5-LOX.
Apoptotic PMN enhance miR-219-2, decrease 5-LOX expression
and restore pro-resolving lipid mediators in exudates. Apoptotic
PMN are protective in vivo
27,28; therefore, we addressed whether
apoptotic PMN activate resolution programs via regulating miR-
219-2 and 5-LOX. Administration of apoptotic PMN (5310
6 cells/
per mouse) at the height of inflammation (12 hrs post initiation)
significantly increased miR-219-2-3p expression (Figure 5 a) and
Figure 3 | SPM distinctly activate select miRNAs. (a) Human macrophages were incubated with RvD1, RvE1, RvD2, or PD1/NPD1 (each at 1 nM) or
vehicle (6 hrs, 37uC) and miR levels determined by qPCR. Vehicle treatment is normalized as 1 (dashed line). Results are mean 6 SEM, n56. *P,0.05
vehicleversusSPM.(b)Usingaluciferase-basedreportersystem,miR-219-1,miR-219-2,miR-146b,miR-208ormockwereco-transfectedwitha5-LOX
39UTR-luciferasereportervectorintohumanmacrophages(48 hrs,37uC).LuminescencewasmonitoredusingSpectraMax3.Relativereducedluciferase
activity of 5-LOX 39UTR reporter was normalized with 39UTR vector control. (c) miR-219-2 or mock were co-transfected with a 5-LOX, COX-1 or,
COX-2orcontrol39UTR-luciferasereportervectorintohumanmacrophagesasin(b).RelativereducedluciferaseactivitiesofrespectivevectorsinmiR-
219-2 overexpressed macrophages were normalized with mock. Results are mean 6 SEM of n54-6 separate donors. *P,0.05 vector control versus
39UTR of 5-LOX.
www.nature.com/scientificreports
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delayed resolution challenges. LM metabolipidomics demonstrated
that the decreased 5-LOX expression also led to a reduction of LTB4
in both groups (Figure 5 c). Conversely, when compared in both
groups, PGD2 (561 vs. 498695 pg/exudate; 151643 vs. 1,2796
558 pg/exudate), 5,15-diHETE (1.861.0 vs. 4.061.4; 56.9611.0 vs.
98.264.3 pg/exudate)andPD1(22.464.4vs.40.666.9;15.561.3vs.
78.5618.0 pg/exudate)biosynthesiswassignificantlyincreasedafter
apoptotic PMN administration. (Figure 5 d-f and Supplementary
Table S2 online). The inset in Figure 5f displays increased PD1/
NPD1:LTB4 ratio produced by the addition of apoptotic PMN.
Together, these results indicate that apoptotic PMN orchestrated
the onset of resolution programs in part via upregulation of miR-
219-2 that led to the downregulation of pro-inflammatory LM and
concomitant upregulation of pro-resolving LM production.
Discussion
In the present report, we investigated the relationship between LM
and resolution phase miR in resolving inflammatory exudates vs. a
delayed resolution system in vivo in murine peritonitis and their
translation to human macrophages. The results document that 1)
miR-219-2 expression is decreased and directly regulates 5-LOX, a
keyenzymeinthebiosynthesisofLMs,2)exudatepro-inflammatory
mediatorsareincreasedwhilepro-resolvinglipidmediatorsdecrease
in delayed resolution compared to self-limited responses, and 3)
apoptotic PMN rescue miR-219-2 expression, reducing LT and
enhancing local SPM production in exudates.
To date, mechanisms associated with the temporal regulation of
unwanted delays in resolution remain of wide interest. Results pre-
sented herein are the first integration of miR expression profiling
with metabolipidomics in inflammatory exudates to define aspecific
miR-LM signature associated with delayed resolution of the acute
inflammatoryresponse.Additionally,theseresultsprovideamolecu-
lar basis to the burgeoning concept that the onset of resolution is
programmed during initial events of inflammation
29. Results in
Figure 1 indicated that, as early as 4 hrs, miR-219-5p expression is
decreased by 2 log orders compared to self-limited challenges. This
decrease in miR-219-5p expression was associated with significant
increases in targeted 5-LOX-derived products including LTB4 and
decreases in SPM including PD1/NPD1 (Figure 2). Of note, SPM
exerttheiractionsinpicogramtonanogramrange(seereviews5and
7 and those references within) and hence are biologically relevant in
low amounts. In this regard, picogram levels of SPM accumulated in
mouse exudates, e.g. 70 pg of LXA4, 1,140 pg of PD1 and 177 pg of
RvD5 in self-limited inflammation, which are functionally relevant.
Importantly, miR-219-5p can be produced by either miR-219-1 or
Figure 4 | miR-219-2 modulates expression of 5-LOX. Human macrophages were transfected with either mock or miR-219-2 (72 hrs, 37uC). (a) miRs
and mRNAs (b,c) were isolated and analyzed using qPCR. (b,d) Proteins were analyzed by flow cytometry and representative flow cytometry histograms
are shown. Results are mean 6 SEM of n56 donors. *P,0.05, mock vs. miR-219-2. Light gray IgG; black, mock; red, miR-219-2.
www.nature.com/scientificreports
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events in acute inflammation and its resolution revealed that miR-
219-1 or miR-219-2 may play a pivotal role in determining whether
inflammation resolves or is delayed and hence has potential for
chronicity.
Of interest, the actions of LMs identified originally with human
cells in vitro
30 and their roles in resolution were demonstrated in
humans
31. Cantharidin-induced blisters were raised to emulate a
sterile self-limited inflammatory event. Two groups emerged; those
individuals that were early resolvers and those that were delayed
resolvers
31. Temporal formation of pro-resolving lipoxin A4 and
the aspirin-triggered 15-epi-LXA4 produced with low-dose aspirin
in these subjects determined whether an individual was an early or
delayedresolver
31.Thesefindingsinhumansdemonstratedthatlow-
dose aspirin is pro-resolving and anti-inflammatory, limiting PMN
entry to the inflammatory loci. Together the present results under-
score that timely controlled production of SPM is an essential com-
ponent of successful complete tissue resolution and termination of
the acute inflammatory response.
Evidence in humans with non-resolving diseases such as asthma
32,
cystic fibrosis
33,34, or localized aggressive periodontitis (LAP) show
impaired production of SPM such as LXA4,R v E 1a n dP D 1 .S p e -
cifically, breath condensates from patients with severe asthma show
significantly less PD1/NPD1 than healthy control individuals
32.A l s o ,
LAP patients have a significant reduction of LXA4 as well as the DHA
metabolome markers 14-HDHA and 17-HDHA in activated whole
bloodcomparedtothoseof matchedhealthy subjects
35. Recent evidence
from a pre-clinical model of obesity and insulin resistance indicates that
lacking PD1/NPD1 in muscle and adipose may exacerbate obesity-
linked inflammation
36. Also, reduced NPD1 and 15-LOX in human
Alzheimer’s disease
37 andestrogendownregulation of theLXA4circuit
38
provide evidence thatfailed resolution mechanisms are demonstrable in
many organ systems throughoutthebody. Thesefindings areconsistent
with the present results, which demonstrate that delayed resolution (in
the high-dose challenge model) is associated with reduced production
of local SPM (Figures 1 and 2). Hence, diminished local levels of
individual SPM may, in part, explain the persistent uncontrolled
inflammation associated with these diseases.
Figure 5 | Apoptotic PMN stimulate resolution programs during acute inflammation. At 12 hrs, apoptotic human PMN (5310
6 PMN/mouse) were
injectedintomouseperitonitisexudatesinitiatedbyzymosan(1 mgor10 mg/mouse;seeFig.1)injection.Exudateswereharvestedat24 hours.(a)miR-
219-2-3p and (b) 5-LOX expression were quantified via qPCR. (A, inset) Representative macrophage and PMN from exudate (I) bright field, (II) DAPI,
(III)Mergedimage.Magnification40X.Representativeofn54separatemurineexudates.(c–f)Bioactivelipidmediatorsandprecursor/pathwaymarkers
wereidentifiedandquantified(seeMaterialsandMethods).Resultsaremean6SEMofn54separatemurineexudates.*P,0.05,**P,0.01.Self-limited
zymosanvs.zymosanplusapoptoticPMN.#p,0.05delayedresolutionzymosanvs.zymosanplusapoptoticPMN.1P,0.05self-limitedzymosanversus
delayed resolution zymosan challenge. Black bars, self-limited; Gray bars, delayed resolution. Z: zymosan, AP: apoptotic PMN.
www.nature.com/scientificreports
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of gene transcripts
39. Notably, the miR-219-2 but not miR-219-19s
binding with the 39 UTR of 5-LOX (Figure 3 b) provides direct evid-
ence for decreased miR-219-2 expression in the delayed resolution
challenges (Figures 1 b, 2 d). miR-219-2 also increased both
15-LOX-I and 15-LOX-II mRNA expression (Figure 4d and Supple-
mentary Figure 3 online), critical enzymes in the biosynthesis of pro-
tectins as well as lipoxins and resolvins in human tissues
7.T h i sw a s
corroborated in vivo, where increased miR-219-2 expression corre-
lated with increased PD1/NPD1 (Figures 1b, 2 c, and f). However,
unlike 5-LOX, in silico analysis (Targetscan, miRanda, miR database,
and MicroTar) suggested that miR-219-2 does not have predicted
pairing sequences with the 39UTR of 15-LOX-I or 15-LOX-II, implic-
ating that miR-219-29s regulatory actions of 15-LOXlikelyresultfrom
indirect mechanisms. In this regard, it is plausible that miR-219-2
tempers the system by decreasing pro-inflammatory LMs via direct
regulation of 5-LOX and LTB4 and increasing pro-resolving LMs
including PD1/NPD1, leading to a resolving milieu.
It is widely appreciated that apoptotic PMN are an integral com-
ponent of the inflammatory response for complete resolution of
acute inflammation
40 and are protective in vivo
27,28. In the present
experiments, apoptotic PMN activated resolution in vivo via the
miR-219-2/5-LOX axis. Along these lines, in both self-limited and
delayedresolutionchallenges,theadditionofapoptoticPMNgavean
increase in miR-219-2 expression and a concomitant reduction in 5-
LOX expression (Figure 5 a, b). In the self-limited inflammation,
there was an increased trend in COX-2 expression at 24 hrs when
apoptotic cells were given (2
-DCt50.05 6 0.02; mean 6 SEM), com-
pared to zymosan alone (2
-DCt50.03 6 0.01). In the delayed resolu-
tionCOX-2mRNAlevelsweremodestlyincreasedinthepresenceof
apoptotic PMN (2
-DCt50.08 6 0.02) compared to zymosan alone
(2
-DCt50.04 6 0.02). However, the changes in mRNA levels were
not statistically significant. These results indicate that COX-2
expression was not significantly regulated at 24 hrs by apoptotic
PMN in both the self-limited inflammation and delayed resolution.
LTB4 levels were also decreased in these exudates, whereas both
PGD2 and PD1/NPD1 (pro-resolving mediators) were increased
(Figure 5 c,d,f). Of note, PGD2 can participate in the control of the
onset of resolution in vivo
41. Also, PD1/NPD1 enhances resolu-
tion
11,12 and has pro-resolving actions in peritonitis, renal ischemic
injury
42, and liver steatosis
43 as well as action in many other animal
diseasemodelsreviewedin
7,26.Hence,theabilityofapoptoticPMNto
regulate miR and LM regulation provides a clear example dem-
onstrating that miR-219-2 regulates the local inflammatory milieu
by decreasing LTB4 and increasing SPM, illustrating a new check-
point control mechanism
44 in resolution.
Taken together, high-dose challenges of the innate immune sys-
tem that give delayed resolution undermine the endogenous resolu-
tion programs and lead to increased pro-inflammatory mediators
and compromised SPM generation in this experimental in vivo sys-
tem. Moreover, the present results provide evidence that in inflam-
matory exudates miR-219-2 is a key regulator of LM and a
component of the active resolution programs that may be relevant
in the pathogenesis of inflammatory diseases and potentially failed
resolution checkpoint mechanisms that can contribute to disease.
Methods
Materials. Recombinant human granulocyte-macrophage colony-stimulating factor
(GM-CSF) was purchased from R&D Systems (Minneapolis, MN, USA). JetPei
macrophage transfection reagent was purchased from PolyPlus Transfection (Illkirch,
France). Primers were either designed or bought from Invitrogen (Carlsbad, CA) or
Qiagen (Germantown, MD). miRNA expression vectors were purchased from Origene
(Rockville, MD). See Supplementary Tables S3 and S4 online for primer and plasmid
sequences, antibodies, and catalog numbers. Resolvin D1 (7S,8R,17S-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) and deuterated labeled PGE2-d4,L T B 4-
d4 and 5S-HETE-d8 were purchased from Cayman Chemical (Ann Arbor, MI, USA).
miScript Reverse Transcription and Omniscript RT Kits were from Qiagen.
Murine peritonitis. Male FVB mice (6-8 week old, Charles River Laboratories,
Wilmington, MA, USA) were administered zymosan A at either 1 mg/mouse or
10 mg/mouse, suspended in 1 ml of sterile saline to initiate peritonitis
11,13,14.A t
selected time intervals, mice were euthanized, peritoneal exudates were collected by
lavaging the peritoneum with Ca
21/Mg
21 free phosphate buffered saline (PBS
2/2,
5 ml),andleukocyteswereenumeratedusingahemocytometerandlightmicroscopy.
Differential cell counts were assessed with Wright-Giemsa staining for microscopy
and flow cytometry. Fluorochrome-conjugated antibodies for flow cytometry were
CD16/32-blockingAb(clone2.462)andratanti-mouseCD11b(Mac-1achain,clone
M1/70)fromBDBioscience(SanJose,CA,USA);Gr-1(Ly-6G;cloneRB6–8C5),and
isotype-matched IgG controls were purchased from eBioscience (San Diego, CA,
USA). All procedures were conducted in accordance with protocols approved by the
Harvard Medical School Standing Committee on Animals guidelines for animal care
(Protocol 02570).
Peripheral blood PMN and preparation of apoptotic PMN. Fresh human
neutrophils(PMN)wereisolatedbydextran–Histopaquedoublegradientfromwhole
blood from healthy volunteers (deidentified) with no medication intake for 2 weeks
before donation (Partners Human Research Committee Protocol no. 88–02642), and
heparin (1 U/mL) was added as anti-coagulant. Informed consents were obtained
from healthy volunteers and PMN were freshly isolated and subjected to incubation
conditions to produce apoptosis (16-20 hrs, 37uC, 5% CO2).
LC-MS/MS-based lipid mediator lipidomics. LC-MS/MS was performed with a
Shimadzu LC-20AD HPLC (Shimadzu Scientific Instruments, Columbia, MD)
equipped with an Agilent Eclipse Plus C18 column (4.6 mm 3 50mm 3 1.8mm)
paired with an ABI Sciex Instruments 3200 Qtrap linear ion trap triple quadrupole
mass spectrometer (Applied Biosystems, Foster City, CA). Instrument control and
data acquisition were carried out using AnalystTM 1.5 software (Applied
Biosystems). The mobile phase consisted of methanol/water/acetic acid (60/40/0.01;
v/v/v) and was ramped to 80/20/0.01 (v/v/v) after 10 min, 100/0/0.01 (v/v/v) after
12 min, and 90/10/0.01 (v/v/v) after 1.5 minutes to wash and equilibrate the column.
Ion pairs from reported multiple reaction monitoring (MRM) methods carried out
earlier
26 were used for profiling and quantification of individual lipid mediators. See
Supplementary Table S1 online for individual MRM transitions. Criteria used for
identification of each LM and pathway markers were carried out as in
26. Briefly, each
wasmatchedusingretentiontimeandatleast6diagnosticionscomparedtosynthetic
standards where available and authentic standards
26. Quantification was performed
using calibration curves for each product and LM, and recoveries determined using
deuterated internal standards (PGE2-d4,L T B 4-d4 and 5(S)-HETE-d8) for each
chromatographic region of interest (for further details, see ref.26).
PBMC isolation and cell culture. Peripheral blood mononuclear cells (PBMC) were
isolated from human whole venous blood by density gradient centrifugation using
HistopaqueH-1077 (Sigma-Aldrich, Inc., St. Louis,MO, USA) and cultured in RPMI
with 10 ng/mL human recombinant GM-CSF (37uC, 5% CO2, 7 days) as in
9.
Transfection of miRs, RNA isolation and real-time PCR. Human macrophages
(2 3 10
6 cells/10 ml) were transfected with pCMV-miR (mock) or miR-219 plasmid
(5 mg) using a macrophage JetPei macrophage transfection reagent (10 mL) and
incubated (72 h, 37uC, pH 7.45)
9. miRNA fractions and large RNAs from human
macrophages were isolated using High Pure miRNA Isolation (Roche Applied
Science, Indianapolis, IN, USA)
9. Omniscript and miScript (Qiagen, Germantown,
MD,USA)wereusedforreversetranscriptionsformRNAsandmiRs.Real-timePCR
reactions were performed with a 7900HT Real-Time PCR thermal cycler (Applied
Biosystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (Qiagen).
Data analysis was carried out using Real-Time PCR software 7900HT version 2.4
(Applied Biosystems). Relative concentrations of genes of interest were determined
using the comparative Ct method after normalizing to the endogenous control. For
analysisofhumanmiRNAs,smallnucleolarRNAU1(RNAU1A;NCBIaccessionno.
NR_004421) was selected as reference miRNA; for mRNAs, GAPDH (NCBI
accession no. NM_002046.3) was used as a control and direct comparison.
CloningofmiRvectorsand39-UTRluciferasereporter.Humanmacrophageswere
co-transfected with miR expression plasmids and luciferase reporter plasmid DNAs
(251 ratio of microRNA vs. reporter) according tomanufacturer’s instructions. After
incubation (37uC, 5% CO2, 48 hrs), luciferase activity was assayed using
SuperLightTM Luciferase Reporter Gene Assay (BioAssay Systems, Hayward, CA)
and measured using a Spectra Max M3 microplate reader (Molecular Devices, Inc.,
Sunnyvale, CA, USA).
Statistics. Statistical significance was assessed using Student’s t-test. P-values ,0.05
were deemed statistically significant.
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